454 related articles for article (PubMed ID: 25543114)
1. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
Lo TF; Hsieh CR
J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114
[TBL] [Abstract][Full Text] [Related]
2. New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan.
Liu YM; Hsieh CR
Health Econ; 2012 May; 21(5):496-513. PubMed ID: 21394819
[TBL] [Abstract][Full Text] [Related]
3. The effects of expanded mental health benefits on treatment costs.
Sasso AT; Lurie IZ; Lee JU; Lindrooth RC
J Ment Health Policy Econ; 2006 Mar; 9(1):25-33. PubMed ID: 16733269
[TBL] [Abstract][Full Text] [Related]
4. An examination of Alzheimer's disease case definitions using Medicare claims and survey data.
Lin PJ; Kaufer DI; Maciejewski ML; Ganguly R; Paul JE; Biddle AK
Alzheimers Dement; 2010 Jul; 6(4):334-41. PubMed ID: 20434960
[TBL] [Abstract][Full Text] [Related]
5. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
Rothbard AB; Lee S; Blank MB
J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
[TBL] [Abstract][Full Text] [Related]
6. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
Hsieh CR; Sloan FA
Value Health; 2008; 11(2):334-44. PubMed ID: 18380646
[TBL] [Abstract][Full Text] [Related]
7. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009.
Lichtenberg FR
Econ Hum Biol; 2014 Mar; 13():107-27. PubMed ID: 23664114
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
Rice DP; Fillit HM; Max W; Knopman DS; Lloyd JR; Duttagupta S
Am J Manag Care; 2001 Aug; 7(8):809-18. PubMed ID: 11519239
[TBL] [Abstract][Full Text] [Related]
9. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
10. Medical management, costs, and consequences of Alzheimer's disease in Germany: an analysis of health claims data.
Brüggenjürgen B; Andersohn F; Ezzat N; Lacey L; Willich S
J Med Econ; 2015 Jun; 18(6):466-73. PubMed ID: 25692902
[TBL] [Abstract][Full Text] [Related]
11. The effect of donepezil therapy on health costs in a Medicare managed care plan.
Hill JW; Futterman R; Mastey V; Fillit H
Manag Care Interface; 2002 Mar; 15(3):63-70. PubMed ID: 11925682
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Fuh JL; Wang SJ
Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
[TBL] [Abstract][Full Text] [Related]
13. Short-term persistence of high health care costs in a nationally representative sample of children.
Liptak GS; Shone LP; Auinger P; Dick AW; Ryan SA; Szilagyi PG
Pediatrics; 2006 Oct; 118(4):e1001-9. PubMed ID: 17015496
[TBL] [Abstract][Full Text] [Related]
14. Pre-diagnosis excess acute care costs in Alzheimer's patients among a US Medicaid population.
Geldmacher DS; Kirson NY; Birnbaum HG; Eapen S; Kantor E; Cummings AK; Joish VN
Appl Health Econ Health Policy; 2013 Aug; 11(4):407-13. PubMed ID: 23700254
[TBL] [Abstract][Full Text] [Related]
15. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
16. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
Fagnani F; Lafuma A; Pechevis M; Rigaud AS; Traykov L; Seux ML; Forette F
Dement Geriatr Cogn Disord; 2004; 17(1-2):5-13. PubMed ID: 14560059
[TBL] [Abstract][Full Text] [Related]
17. The importance of proximity to death in modelling community medication expenditures for older people: evidence from New Zealand.
Moore PV; Bennett K; Normand C
Appl Health Econ Health Policy; 2014 Dec; 12(6):623-33. PubMed ID: 25141830
[TBL] [Abstract][Full Text] [Related]
18. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.
Chen LC; Schafheutle EI; Noyce PR
Res Social Adm Pharm; 2009 Sep; 5(3):211-24. PubMed ID: 19733822
[TBL] [Abstract][Full Text] [Related]
19. Use of cognitive enhancers and associated medical care costs among patients with dementia: a nationwide study in Taiwan.
Ku LJ; Pai MC
Int Psychogeriatr; 2014 May; 26(5):795-804. PubMed ID: 24429098
[TBL] [Abstract][Full Text] [Related]
20. The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan.
Liu YM; Yang YH; Hsieh CR
Soc Sci Med; 2011 Mar; 72(6):919-27. PubMed ID: 21333432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
